CHEK1 and vulva cancer: In order to investigate the effect of CHK1 targeting in vulvar cancer, we treated CAL39 and SW954 cell lines with increasing concentrations (0.063‐2 μmol/L) of the commercially available CHK1/CHK2 inhibitor AZD7762 for up to 5 days.